Repatha vs Lisinopril: Switching Between Them and What Every Woman Should Know

What Are These Two Drugs Actually Doing?

Repatha and lisinopril do not compete for the same job. Repatha targets your LDL cholesterol by blocking a protein called PCSK9, which normally degrades LDL receptors on your liver. Lisinopril targets your blood pressure by blocking angiotensin-converting enzyme, reducing the production of angiotensin II and relaxing your blood vessels. A cardiologist might prescribe both to the same woman simultaneously, because high cholesterol and high blood pressure are separate, co-occurring problems.

This distinction matters before you read any "vs" comparison: the question of switching between them only makes sense if your prescriber is reconsidering your entire cardiometabolic treatment plan, not simply swapping one pill for another.

How Each Drug Works in the Body

Evolocumab (Repatha) is a monoclonal antibody given as a subcutaneous injection, either 140 mg every two weeks or 420 mg once monthly. It binds PCSK9, preventing that protein from breaking down LDL receptors, so your liver clears more LDL from your bloodstream. In the FOURIER trial (NEJM 2017), evolocumab reduced LDL-C by a median of 59% on top of statin therapy, bringing median LDL down to 30 mg/dL.

Lisinopril is a small oral molecule, typically dosed between 10 mg and 40 mg once daily for hypertension, and up to 40 mg for heart failure. It inhibits ACE, which in turn lowers angiotensin II and aldosterone, reducing vasoconstriction and sodium retention. In the ALLHAT trial (JAMA 2002), lisinopril produced equivalent combined cardiovascular outcomes to chlorthalidone overall, though it performed worse on stroke prevention, especially in Black participants.

Which Conditions Each Drug Is Approved For

Repatha carries FDA approval for adults with heterozygous or homozygous familial hypercholesterolemia, established atherosclerotic cardiovascular disease (ASCVD), and as an adjunct to diet in adults who need additional LDL-C lowering beyond maximally tolerated statin therapy. Lisinopril is approved for hypertension, heart failure, and acute myocardial infarction to improve survival. The overlap, if any, is in the woman who has established ASCVD with both high LDL and high blood pressure, where both drugs might appear on the same prescription pad at the same time.

The Evidence Base and What It Means for Women

Neither FOURIER nor ALLHAT was designed with women's cardiovascular biology as a primary focus, and this matters.

FOURIER Trial: What It Showed and the Women's Data Gap

The FOURIER trial enrolled 27,564 patients with established ASCVD who were already on optimized statin therapy. Evolocumab reduced the risk of major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, by a relative 15% compared to placebo. The absolute risk reduction was 1.5 percentage points over a median follow-up of 2.2 years.

Only approximately 25% of FOURIER participants were women. Sex-stratified subgroup analyses showed that the direction of benefit was consistent for women, but the trial was not powered to detect statistically significant sex-specific differences in MACE. This is a real evidence gap. Women's cardiovascular disease often presents a decade later than men's, occurs more frequently without obstructive coronary artery disease, and is driven differently by hormonal status across the lifespan. Extrapolating FOURIER's aggregate benefit directly to a 48-year-old perimenopausal woman with familial hypercholesterolemia requires clinical judgment, not certainty.

A practical framework for interpreting FOURIER data across women's life stages:

| Life Stage | LDL Pattern | Clinical Consideration | |---|---|---| | Reproductive years (18-40) | Often lower estrogen-influenced LDL | FH risk may be masked; PCSK9 inhibitors contraindicated in pregnancy | | Perimenopause (40s-early 50s) | LDL rises sharply as estrogen falls | ASCVD risk accelerates; FOURIER benefit most directly applicable here | | Post-menopause | Sustained elevated LDL, increased ASCVD risk | Strongest trial-applicable population for evolocumab | | Familial hypercholesterolemia (any age) | Severely elevated LDL from birth | Evolocumab may be indicated earlier regardless of life stage |

ALLHAT Trial: Blood Pressure Evidence and the Sex and Race Nuance

ALLHAT enrolled 33,357 participants aged 55 and older with hypertension and at least one additional coronary heart disease risk factor. Women made up approximately 47% of ALLHAT. The trial found that lisinopril did not differ from chlorthalidone on the primary outcome (fatal coronary heart disease or nonfatal MI), but lisinopril was significantly worse on secondary stroke outcomes, particularly in Black participants, where chlorthalidone reduced stroke by 40% more than lisinopril.

For women specifically, ALLHAT provides more sex-representative data than FOURIER does, but the trial still did not examine hormonal status, menopausal transition, or the interaction between ACE inhibition and estrogen decline. The perimenopausal period, when blood pressure often rises due to declining estrogen and increasing sympathetic nervous system activity, is precisely when many women are first prescribed ACE inhibitors. The ALLHAT trial does not speak to this population directly.

Sex-Specific Physiology: How Being Female Changes Things

LDL and Hormonal Status

Estrogen up-regulates hepatic LDL receptor expression, which is why premenopausal women typically have lower LDL than age-matched men. After menopause, this protective effect disappears. LDL-C can rise by 10 to 20 mg/dL in the years surrounding the final menstrual period, independently of diet or weight change. A woman whose LDL was 110 mg/dL at 45 may find it at 135 mg/dL at 52 with no lifestyle changes whatsoever. This hormonal shift is one reason PCSK9 inhibitors are increasingly relevant to perimenopausal and postmenopausal women with borderline-high or high cardiovascular risk.

Blood Pressure and the Menopause Transition

Blood pressure regulation is tightly linked to hormonal status in women. Premenopausal women generally have lower blood pressure than age-matched men. After the menopause transition, that advantage disappears, and hypertension prevalence in women over 65 exceeds that in men of the same age. ACE inhibitors like lisinopril are first-line options in this group, particularly when diabetes-related kidney protection is also a goal. Women with PCOS and insulin resistance may develop hypertension a decade earlier than the general population, making earlier ACE inhibitor initiation a consideration even in the reproductive years.

ACE Inhibitor Cough: More Common in Women

A dry, persistent cough affects roughly 10 to 15% of patients on ACE inhibitors overall, but studies consistently show women experience this side effect at approximately twice the rate of men. If you develop a cough on lisinopril, this is not a reason to push through. Your prescriber can switch you to an angiotensin receptor blocker (ARB) such as losartan or valsartan, which provides equivalent blood pressure control without the cough mechanism.

Injection-Site Reactions with Evolocumab

Repatha is injected subcutaneously. Injection-site reactions, including redness, swelling, and bruising, occur in approximately 6% of users. No sex-specific data on injection-site reaction rates in women specifically is available from FOURIER, but subcutaneous fat distribution differences between sexes mean technique and site rotation matter. The outer thigh, abdomen, and upper arm are all acceptable sites; rotating systematically reduces local reactions.

Pregnancy, Lactation, and Contraception: A Required Section for Both Drugs

Both Repatha and lisinopril require serious pregnancy counseling. Neither is acceptable during pregnancy, and for different but equally urgent reasons.

Lisinopril: A Confirmed Teratogen

Lisinopril is contraindicated throughout pregnancy. ACE inhibitor exposure during the second and third trimesters causes fetal renal tubular dysplasia, neonatal renal failure, oligohydramnios, limb contractures, craniofacial deformities, and neonatal death. This is not a theoretical risk; it is documented in multiple case series and cohort studies. Even first-trimester exposure has been associated with cardiovascular and CNS malformations, though the evidence is less definitive than for later trimesters. If you are of reproductive age and sexually active, your prescriber must document your contraception plan before or at the time lisinopril is prescribed. If you become pregnant while on lisinopril, discontinue it immediately and contact your care team that day.

During lactation, lisinopril is excreted in breast milk in small amounts. The FDA labeling advises against use during breastfeeding, and the LactMed database recommends alternatives such as nifedipine or labetalol for postpartum women requiring blood pressure management who are breastfeeding.

Repatha (Evolocumab): Avoid in Pregnancy, Inadequate Human Data

Repatha has no adequate well-controlled studies in pregnant women. Animal studies at high doses showed no direct fetal harm, but PCSK9 plays a role in fetal lipid metabolism, and cholesterol is necessary for normal fetal development and placental function. The FDA advises avoiding evolocumab during pregnancy on the basis of insufficient safety data. Because PCSK9 inhibitors target a pathway involved in cholesterol synthesis and because fetal cholesterol is critical for neural and hormonal development, the theoretical risk is not negligible even without confirmed human teratogenicity data.

For women of reproductive age with familial hypercholesterolemia who need aggressive LDL lowering, the conversation about conception planning must happen before Repatha is initiated. If pregnancy is desired in the near term, the prescriber may choose to defer PCSK9 inhibitor therapy or discuss the risk-benefit in detail.

Regarding lactation: it is unknown whether evolocumab passes into human breast milk. Because the potential for harm to a nursing infant is unknown, the FDA labeling recommends caution, and most clinicians advise against use during breastfeeding.

Contraception Requirement Summary

| Drug | Pregnancy Status | Lactation Status | Contraception Requirement | |---|---|---|---| | Lisinopril | Contraindicated (confirmed teratogen) | Avoid; use alternatives | Reliable contraception required in reproductive-age women | | Repatha | Avoid (insufficient data) | Unknown; avoid | Discuss conception plans before initiating |

Who Should Be on Repatha, Who Should Be on Lisinopril, and Who Needs Both

These drugs are not alternatives to each other. Framing helps.

Women Who Are Candidates for Repatha

You may be a candidate for evolocumab if you have established ASCVD (prior heart attack, stroke, or peripheral artery disease) and your LDL-C remains above 70 mg/dL despite maximally tolerated statin therapy, or if you have heterozygous or homozygous familial hypercholesterolemia. Postmenopausal women with familial hypercholesterolemia who have not yet had a cardiovascular event but carry a very high 10-year ASCVD risk are also a population where some guidelines support PCSK9 inhibitor use, though the evidence base for primary prevention is thinner than for secondary prevention.

Repatha is not appropriate for women with high blood pressure as their only cardiometabolic problem, and it does not lower blood pressure.

Women Who Are Candidates for Lisinopril

Lisinopril is appropriate for women with hypertension, particularly those who also have diabetes (where kidney-protective effects of ACE inhibition add value), heart failure with reduced ejection fraction, or who have had a myocardial infarction. Women with PCOS who develop hypertension alongside insulin resistance may be candidates earlier in life.

Lisinopril does not lower LDL or reduce cardiovascular events through cholesterol pathways. If your primary cardiometabolic problem is elevated LDL and established ASCVD, lisinopril alone does not address that risk.

Women Who Need Both

A postmenopausal woman with a history of myocardial infarction, LDL of 95 mg/dL on rosuvastatin 20 mg, and blood pressure of 148/92 mmHg is a candidate for both evolocumab and lisinopril simultaneously. These drugs do not interact pharmacologically with each other. Adding evolocumab to her statin would target LDL reduction, while lisinopril targets blood pressure and cardiac remodeling. This combination is clinically common and appropriate.

What "Switching Between Them" Actually Means in Clinical Practice

The phrase "switching from Repatha to lisinopril" or vice versa almost never describes a clinical scenario where one drug is discontinued and the other started as a replacement. Because these drugs address different conditions, a prescriber who discontinues Repatha is usually replacing it with another lipid-lowering agent (another PCSK9 inhibitor like alirocumab, or inclisiran, or ezetimibe), not with lisinopril. Similarly, a prescriber who discontinues lisinopril is usually replacing it with another antihypertensive (an ARB, a calcium channel blocker, or a thiazide diuretic), not with Repatha.

The scenario where both appear in a "switching" conversation most often involves a woman whose entire cardiometabolic regimen is being restructured, perhaps after pregnancy (where both were stopped), after a new ASCVD event prompting more aggressive LDL therapy, or after a side effect (like the lisinopril cough) that requires a class change on the blood pressure side while the lipid side is simultaneously optimized.

If your prescriber is recommending stopping one and starting the other, ask directly: what problem is each drug solving, and why is the first drug no longer the right solution for that specific problem?

Cost, Access, and Practical Considerations for Women

Lisinopril is among the least expensive medications in the United States. A 30-day supply at standard doses costs under $10 at most pharmacies, and it is on virtually every generic formulary.

Repatha is dramatically more expensive. The list price runs approximately $5,800 to $6,600 per year. Manufacturer copay assistance programs (Amgen's Repatha Connect) can reduce out-of-pocket cost to as low as $5 per month for commercially insured patients, but Medicare and Medicaid beneficiaries often face prior authorization hurdles. Payers typically require documented statin intolerance or failure, LDL above a threshold despite statin use, and often a formal cardiology consultation before approving Repatha.

For women managing these costs on fixed incomes in the postmenopausal years, access to evolocumab is a real barrier that your care team should help you manage proactively.

Monitoring and Follow-Up by Life Stage

Reproductive Years (18 to 40)

Women on lisinopril in this age group need pregnancy testing and contraception counseling at every visit. Blood pressure, potassium, and creatinine should be checked within two to four weeks of dose changes. Women with PCOS or early-onset hypertension in this group benefit from annual metabolic panels.

Women on Repatha in this group are most likely to have familial hypercholesterolemia. LDL-C should be checked six to eight weeks after initiation and then every three to twelve months once at goal. Pregnancy planning conversations must be documented.

Perimenopause (40s to Early 50s)

Blood pressure monitoring becomes more urgent during perimenopause, as sympathetic nervous system dysregulation can produce significant BP variability. Home blood pressure monitoring with a validated device, twice daily for two weeks, gives your prescriber much more useful data than a single office reading. LDL-C monitoring during this period should also intensify, given the estrogen-withdrawal effect on LDL receptor expression.

Post-Menopause (50s Onward)

This is the life stage where most women with established ASCVD are living, and where both drugs are most commonly co-prescribed. Annual kidney function and electrolyte panels are appropriate for women on lisinopril. LDL-C monitoring for women on evolocumab can extend to every six to twelve months once stable, per the ACC/AHA Cholesterol Guideline.

The Evidence Gap: What We Still Do Not Know in Women

Clinical trials in cardiovascular disease have systematically under-enrolled women for decades. FOURIER enrolled only about 25% women, and the sex-stratified MACE data, while directionally consistent with benefit, was not statistically powered for female-specific conclusions. ALLHAT did better at 47% female enrollment but still did not examine how menopausal status, estrogen therapy, or hormonal contraception interact with ACE inhibition.

The absence of sex-specific data is not reassurance. When your prescriber recommends either drug, the benefit-risk calculation is being made partly on evidence from populations where women were a minority. Asking your prescriber "what do the sex-stratified data show specifically?" is a reasonable and informed question.